Medtech giant Medtronic has successfully seen two patents for its sacral neuromodulation (SNM) upheld before US courts, opening the way for a lawsuit against bladder and bowel company Axonics.

Medical device giant Medtronic was hit with three lawsuits in the District of Delaware on Nov. 12—two by the previous ...

Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...

including as a result of the Medtronic Litigation; introductions and announcements of new technologies by Axonics, any commercialization partners or Axonics’ competitors, and the timing of these ...

IRVINE, Calif., September 18, 2024--Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics ...

To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Medtronic has received Food and Drug Administration approval to study its Affera mapping and ablation ...

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the ...

Medtronic MDT underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their recent ...

Piper Sandler analyst Matthew O’Brien maintained a Hold rating on Medtronic (MDT – Research Report) today and set a price target of $90.00. The company’s shares closed yesterday at $90.99.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...